These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37260251)

  • 41. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.
    Ayele HT; Mourik MS; Debray TP; Bonten MJ
    PLoS One; 2015; 10(11):e0142290. PubMed ID: 26551023
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana.
    Sibanda T; Tedla Z; Nyirenda S; Agizew T; Marape M; Miranda AG; Reuter H; Johnson JL; Samandari T
    Int J Tuberc Lung Dis; 2013 Feb; 17(2):178-85. PubMed ID: 23317952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009.
    Jenkins HE; Zignol M; Cohen T
    PLoS One; 2011; 6(7):e22927. PubMed ID: 21829557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.
    Jahng AW; Tran T; Bui L; Joyner JL
    Transplantation; 2007 Jun; 83(12):1557-62. PubMed ID: 17589337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
    Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
    Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease.
    Mohammed A; Myer L; Ehrlich R; Wood R; Cilliers F; Maartens G
    Int J Tuberc Lung Dis; 2007 Oct; 11(10):1114-20. PubMed ID: 17945069
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
    van Griensven J; Choun K; Chim B; Thai S; Lorent N; Lynen L
    Trop Med Int Health; 2015 Dec; 20(12):1823-31. PubMed ID: 26426387
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
    Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
    Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
    Samandari T; Agizew TB; Nyirenda S; Tedla Z; Sibanda T; Shang N; Mosimaneotsile B; Motsamai OI; Bozeman L; Davis MK; Talbot EA; Moeti TL; Moffat HJ; Kilmarx PH; Castro KG; Wells CD
    Lancet; 2011 May; 377(9777):1588-98. PubMed ID: 21492926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children.
    Gray DM; Zar H; Cotton M
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006418. PubMed ID: 19160285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. INH preventive therapy among adult HIV-infected patients in Thailand.
    Hiransuthikul N; Nelson KE; Hiransuthikul P; Vorayingyong A; Paewplot R
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):270-5. PubMed ID: 15786889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Empiric vs screening-based use of isoniazid for tuberculosis prophylaxis: Safety and effectiveness in lung transplant recipients in Saudi Arabia.
    Korayem GB; Alissa DA; AlSuhaibani NI; AlSwailem GS; AlShammari MA; Yaqoob I; Aljasser DS; Almaghrabi RS
    Transpl Infect Dis; 2021 Apr; 23(2):e13473. PubMed ID: 32978858
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents.
    Bourré-Tessier J; Arino-Torregrosa M; Choquette D
    Clin Rheumatol; 2014 Aug; 33(8):1049-53. PubMed ID: 24554383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Adverse effect other than liver dysfunction in treatment of latent tuberculous infection by isoniazid].
    Ito K; Hoshino H; Nakazono T; Masuyama H; Sugita H; Yoshiyama T; Kato S
    Kekkaku; 2007 Jan; 82(1):1-9. PubMed ID: 17310776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.
    Golub JE; Cohn S; Saraceni V; Cavalcante SC; Pacheco AG; Moulton LH; Durovni B; Chaisson RE
    Clin Infect Dis; 2015 Feb; 60(4):639-45. PubMed ID: 25365974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High Burden of Adverse Drug Reactions to Isoniazid Preventive Therapy in People Living With HIV at 3 Tertiary Hospitals in Uganda: Associated Factors.
    Nanyonga SM; Kitutu FE; Kalyango J; Frank M; Kiguba R
    J Acquir Immune Defic Syndr; 2022 Feb; 89(2):215-221. PubMed ID: 34693930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatotoxicity Induced by Isoniazid-Lipopolysaccharide through Endoplasmic Reticulum Stress, Autophagy, and Apoptosis Pathways in Zebrafish.
    Zhang Y; Cen J; Jia Z; Hsiao CD; Xia Q; Wang X; Chen X; Wang R; Jiang Z; Zhang L; Liu K
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area.
    Moon HH; Park SY; Kim JM; Park JB; Kwon CHD; Peck KR; Kim SJ; Lee SK; Joh JW
    Ann Transplant; 2017 Jun; 22():338-345. PubMed ID: 28579606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
    Ocama P; Katwere M; Piloya T; Feld J; Opio KC; Kambugu A; Katabira E; Thomas D; Colebunders R; Ronald A
    Afr Health Sci; 2008 Mar; 8(1):8-12. PubMed ID: 19357726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.